New schizophrenia drug shows promise in phase 2 trial
Disease control
Completed
This study tested a new medicine called LB-102 in 359 adults with acute schizophrenia. The goal was to see if it reduces symptoms like hallucinations and confusion better than a placebo over 28 days. Researchers measured changes using standard symptom scales and also checked safe…
Phase: PHASE2 • Sponsor: LB Pharmaceuticals Inc. • Aim: Disease control
Last updated May 17, 2026 09:11 UTC